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Introduction
Breast cancer is not a single disease but rather a group of heterogeneous tumours at the molecular level(1). Based on the knowledge that certain biological features of cancers may indicate an increased likelihood of rapid growth and metastasis (in particular, distant recurrence) gene expression profiling (GEP) and expanded immunohistochemistry (IHC) (or protein expression) tests have been developed.
These tests have an aim of improving the targeting of chemotherapy in breast cancer by stratifying patients and identifying those patients who will gain most benefit from adjuvant chemotherapy. These tests either measure the risk of cancer recurrence (by incorporating a wider range of biomarkers with prognostic significance than standard clinico-pathological algorithms), or aim to identify breast cancer sub-types which may influence recurrence risk and guide treatment decisions.
In current practice treatment regimens are tailored according to traditional clinical characteristics such as age, tumour size and grade together with a tumour's molecular signature based on estrogen (ER) and progesterone (PR) receptor status and HER2 receptor status(2), although guidelines may differ slightly from country to country.
The purpose of this systematic review was to evaluate the clinical effectiveness of GEP and expanded IHC tests in guiding the use of adjuvant chemotherapy in women with early breast cancer. A summary of the evaluated gene expression profiling and expanded immunohistochemistry tests is presented in Table 1 . This review was originally undertaken to inform the UK National Institute for Health and Care
Excellence's (NICE) assessment of GEP (MammaPrint, OncotypeDX) and IHC (IHC4 and Mammostrat) tests to guide selection of chemotherapy regimens in breast cancer management(3), but has been updated with new evidence up to May 2016. Table 1 here
Method
A systematic review of the evidence was undertaken according to the general principles recommended in the Centre for Reviews and Dissemination (CRD)(4) guidance for undertaking systematic reviews, and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) The search strategy used free text and thesaurus terms and combined breast cancer related synonyms (e.g. breast neoplasm) with terms related to gene expression profiling tests or biomarkers (e.g. MammaPrint or "gene?twentyone"). A publication date limit of January 2002 was applied. This was the date that the longest standing test used in the review had been devised, as confirmed by manufacturers' submissions to NICE as part of the original review, and therefore it would not be possible for evidence to predate this. For the OncotypeDX and MammaPrint test, the current review used two previous systematic reviews (7, 8) to identify included studies, thus the searches were limited from January 2009 (last date from earlier reviews) for these tests. Although a number of other systematic reviews examining GEP tests have been reported, these reviews(7,8) were considered the most appropriate reviews to update. The reviews were assessed as being of high quality, and in particular the search strategies were assessed as being complete. No other limits were applied to the searches. An update search was conducted in Medline and Medline in Process from January 2013 -May 2016.
Supplementary search techniques were also undertaken to augment the topic searches, these included hand searching of relevant journals, citation searches of included papers in the review, searching of conference proceedings, and finally experts in the field were contacted to ask for suggestions for relevant evidence for the project.
Study selection
The inclusion of potentially relevant articles was undertaken using a two-stage process. First, all titles and abstracts were screened for inclusion, followed by the assessment of full manuscripts. Both stages were undertaken by one reviewer and any uncertainties in the selection process were resolved through discussion with another reviewer. All study designs were included. Eligible studies included adult patients diagnosed with early invasive breast cancer. The index test included OncotypeDX, MammaPrint, IHC4 or Mammostrat. The comparator was standard care and could include the use of Adjuvant! Online (AoL) and/or the Nottingham Prognostic Index (NPI), to predict the risk of recurrence and survival for patients with early breast cancer. The outcome measure was clinical utility (the test's ability to discriminate between those who will have more or less benefit from a therapeutic intervention) (7,8). Specifically, (i) the ability of the test to predict treatment effect with adjuvant chemotherapy, and (ii) to what extent are test results used in treatment decisions. Studies published in languages other than English (unless no other comparable data existed) were excluded. Abstracts were considered but only included if they represented significant new knowledge, such as prospective RCT evidence.
Data extraction and quality assessment Data relating to study design, methodological quality, and outcomes, were extracted by one reviewer into a standardised data extraction form and independently checked for accuracy by a second.
Discrepancies were resolved by discussion. The methodological quality of each included study was assessed by two reviewers according to the criteria recommended by Altman (2001)(9) for assessing the internal validity of prognostic (predictive factor) studies.
Data synthesis and analysis
Although a meta-analysis was planned, this was not considered appropriate due to a high degree of heterogeneity e.g. study populations, outcomes and diagnostic thresholds between and within studies. Therefore, data were tabulated and discussed in a narrative review.
Results

PRISMA flow
Figure 1 summarises the process of identifying and selecting relevant literature. Of the 7064 citations identified, 29 new studies (30 citations) were identified and were added to the 11 studies from the previous systematic reviews. Most of the evidence was related to the OncotypeDX (32 studies). Four studies related to the prediction of treatment effect with adjuvant chemotherapy, with the remaining 28 studies relating to evidence on the test result leading to changes in treatment decisions. Six studies were identified for MammaPrint, all relating to evidence on the test result leading to changes in treatment decisions. Only one relevant study was identified for IHC4, and one for Mammostrat. The IHC4 study provided evidence relating to the test leading to changes in treatment decisions, whereas the Mammostrat study provided evidence on the prediction of treatment effect with adjuvant chemotherapy. Details of the study and patient characteristics, together with key findings of the included studies are provided in Tables 2 and 3 .
Quality Assessment
Limitations in the clinical data were identified for all tests. No studies had a prospective, randomised controlled trial (RCT) design and only five studies included a prospective analysis of archived tissue samples from a previous RCT (OncotypeDX n=4; Mammostrat n=1). For the four OncotypeDX studies and the one Mammostrat study providing evidence relating to the prediction of treatment effect with adjuvant chemotherapy, the overall risk of bias was judged to be moderate, although retrospective analysis of archived tissue samples, the evidence was derived from relatively large scale RCTs. The remaining 28 OncotypeDX studies providing evidence relating to changes in treatment recommendations, were in the main, small scale studies (n=25-979). Fifteen were retrospective in study design, and some (n=14) did not provide full details of the patient characteristics. Similarly, of the six studies identified for MammaPrint two were retrospective in study design, and some were lacking full details of patient characteristics. The IHC4 study was prospective in design, however the sample size was relatively small (n=124).
Overall, particularly for the studies relating to evidence of the tests leading to changes in treatment decisions, there was a high level of clinical heterogeneity across studies both within each test and across the four tests. demonstrated that the RS was prognostic for tamoxifen-treated patients with positive nodes and predicts significant benefit of chemotherapy in tumours with a high recurrence score. They concluded that a low score could identify women who might not benefit from anthracycline-based chemotherapy, despite positive nodes.
It was also reported by Tang, Shak and Paik et al.(12) that both RS and AoL provided strong independent prognostic information in tamoxifen treated patients, and that RS used alone remained the best predictor of chemotherapy benefit in ER+, LN-breast cancer(13).
Of these four studies reporting evidence that OncotypeDX predicts benefit from chemotherapy, only one, on a LN+ population(11) presented that had not come from the NSABP cohorts. However, there were limitations associated with this study. It had only a moderate sample size, and the time over which tumour samples were collected was not reported, therefore they may be differences in diagnostic criteria However, where this was reported the number of patients being recommended chemotherapy after the test was introduced declined in most studies. This change from chemotherapy to no chemotherapy ranged from 6% to 51 .4% of all patients tested. However, in one study more chemotherapy was used after the introduction of OncotypeDX(28). It was not clear in a large number of the studies whether these figures represented actual changes in the treatments patients received.
MammaPrint
Six studies were identified which provided evidence on changes in treatment recommendations as a result of MammaPrint (see table 3 ). These studies indicated that the use of MammaPrint in addition to clinicopathological factors led to changes in treatment recommendations for between 18% and 40% of all patients tested, and that the between 2% and 32% of all patients would be recommended to change from chemotherapy to no chemotherapy. One of these studies (45) A prospective observational study (43) showed that adjuvant treatment was recommended for 48% of patients based on, and Dutch Institute for Healthcare Improvement (CBO) guidelines (2004) alone, increasing to 62% when MammaPrint was added. This increased the number of patients receiving adjuvant systemic therapy by 20 (5%). For the other guidelines assessed (St Gallen guidelines, the NPI and AoL), less adjuvant chemotherapy would be given when the data was based on prognostic signature alone are used. A 5 year follow up study (44) showed that 15% of the MammaPrint low risk patients received adjuvant chemotherapy versus 81% of the high-risk patients. The 5 year distant recurrence free interval (DRFI) probabilities for MammaPrint low-risk patients were 97%, and 91.7% for the high-risk patients. Actual treatment decisions were based on restrictive CBO guidelines, and doctors and patients preferences limiting the generalisability of these findings.
IHC4
Evidence from one prospective study (50) demonstrated that the IHC4 test led to changes in treatment recommendations for 34% of the patients, with 25%
recommended to switch from chemotherapy to no chemotherapy. As there is only one study available and it has a small sample size (n=124), it is difficult to make generalisations based on this evidence. Again, it is not clear whether actual treatment given was changed.
Discussion
OncotypeDX currently has the largest body of evidence on clinical utility relative to the other three tests included in this review. Although, no prospective studies reporting the impact of OncotypeDX on long term outcomes, such as overall survival, yet exist. The Paik, Tang and Shak et al.(10) study represented the most robust evidence of clinical utility. The study showed a decreased relative benefit of chemotherapy in the lower-risk groups. However, the specific cancers in the low-risk groups were less likely to respond to chemotherapy, independent of actual survival probability. Other specific limitations include that fact that in one study (32), compared to the study regimens, more effective chemotherapy regimens are currently being used, and more than 44% of patients were aged below 50 years old, limiting the generalisability of the findings.
The evidence base for MammaPrint, is primarily based on small sample sizes (n<427). Some studies were retrospective in design and had heterogeneous patient populations. Some studies included only pre-menopausal women, which may overestimate the benefit of MammaPrint in the early breast cancer population as a whole, given that younger women are likely to be at higher risk of recurrence and are more likely to be classified as poor prognosis using MammaPrint. Further evidence is required to clarify whether using the test will improve the use of adjuvant chemotherapy in the management of breast cancer. It is also unclear to what extent MammaPrint risk groups are predictive of chemotherapy benefit or how the use of MammaPrint will improve patient outcomes through increases in disease-free and overall survival.
One study on Mammostrat(14) provides evidence relating to the benefit of chemotherapy by risk group. However, this indicates that both low and high-risk groups benefit, whilst it is unclear how those in the moderate risk group would be affected. Further evidence is required. In particular there was no published evidence on the impact of the test on decision-making.
One clinical utility study was available for IHC4 (50) . This study provided evidence on the impact of the test on decision-making leading to reductions in the amount of chemotherapy recommended. Although the design was prospective it included a relatively small sample of patients.
Limitations
The varied nature of the evidence base makes comparisons between tests difficult.
A characteristic feature of the studies across all tests was their heterogeneity, and a large proportion of the studies were small. Many studies used old archived tumour samples, and some, retrospective chart review to elicit treatment recommendations before and after testing. There was a lack of standardised decision-making tools both within and between studies and non-standardised methods of patient selection were used. Furthermore, a number of the studies for OncotypeDX and MammaPrint were funded by the manufacturer giving rise to potential issues of conflict of interests and publication bias.
Conclusion and Implications
One of the tests (OncotypeDX) has a reasonably large evidence base, although there are some methodological weaknesses relating to this evidence, in terms of heterogeneity of patient cohorts, and retrospective study design. The previous systematic reviews(7,8) on which our updates were based reported that OncotypeDX was furthest along the validation pathway, and that recurrence score was significantly correlated with disease-free-survival and overall survival. There was also some evidence that there may be a significant benefit from the use of chemotherapy in the OncotypeDX high-risk group, although it was acknowledged that this study may have been subject to bias. Our previous review (3) and this update demonstrates that further larger studies have now reported, which support the prognostic capability of the OncotypeDX test, and in the evidence base has been 
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